2. Academic Validation
  3. Advancing vaccine development: Evaluation of a mannose-modified lipid nanoparticle-based candidate for African swine fever p30 mRNA vaccine eliciting robust immune response in mice

Advancing vaccine development: Evaluation of a mannose-modified lipid nanoparticle-based candidate for African swine fever p30 mRNA vaccine eliciting robust immune response in mice

  • Int J Biol Macromol. 2024 May 17;270(Pt 1):132432. doi: 10.1016/j.ijbiomac.2024.132432.
Lele Gong 1,  Yuanyuan Zhang 1,  Lele Wang 1,  Xuyang Zhao 1,  Lucai Wang 1,  Xiangqi Qiu 1,  Xilong Yang 1,  Wenhui Zhu 1,  Lijie Lv 1,  Yunzhe Kang 1,  Yanan Wu 1,  Angke Zhang 1,  Yongkun Du 1,  Xuannian Wang 1,  Gaiping Zhang 2,  Aijun Sun 3,  Guoqing Zhuang 4
Affiliations

Affiliations

  • 1 College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China.
  • 2 College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; Longhu Laboratory of Advanced Immunology, Zhengzhou 450046, China; School of Advanced Agriculture Sciences, Peking University, Beijing 100871, China.
  • 3 College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China. Electronic address: sunaijun225@163.com.
  • 4 College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China. Electronic address: gqzhuang2008@163.com.
PMID: 38761609 DOI: 10.1016/j.ijbiomac.2024.132432
Abstract

The African swine fever virus (ASFV) continues to pose significant economic and pandemic risks. Consequently, discovering new, efficient vaccines is crucial. Messenger RNA (mRNA) vaccines have emerged as promising candidates, providing minimal risk of insertional mutagenesis, high safety profiles, effectiveness, rapid scalability in production, and cost-effectiveness. In this study, we have developed an ASF p30 mRNA vaccine candidate (mRNA/Man-LNP) employing mannose-modified lipid nanoparticles (LNPs). The mRNA/Man-LNP exhibited effective antigen presentation and facilitated dendritic cells (DCs) maturation. Notably, it elicited strong IgG titers and activated CD4+ and CD8+ T-cells in immunized mice, all while adhering to stringent biosafety standards. This investigation demonstrates that mRNA/Man-LNP can trigger both humoral and cellular immune responses, suggesting its potential as a potent and promising vaccine candidate for controlling African swine fever (ASF).

Keywords

African swine fever virus; Delivery system; Mannose modification; mRNA vaccine; p30.

Figures
Products